

**NIGERIA**

**ACE Centre**

**African Centre of Excellence for Genomics of Infectious Diseases (ACEGID)**

**INTERIM FINANCIAL REPORT (IFR)**

**FOR THE PERIOD ENDED - DECEMBER 31, 2023**

**Prepared: Project Accountant, Mr. Idowu Olaoluwa Afolabi**

**Reviewed By: A.g Bursar, Mrs. Patience Osiofenoya Saliu**

PROJECT IMPLEMENTING ENTITY:		NIGERIA				
PROJECT NAME:		African Centre of Excellence for Genomics of Infectious Diseases (ACEGID)				
IBRD CREDIT/GRANT NO.		IDA / R2014 – 0089				
REPORT:		INTERIM FINANCIAL REPORT (IFR)				
THIS SCHEDULE:		STATEMENT OF SOURCES AND USES OF FUNDS -By Components				
PERIOD OF REPORT:		ENDING - DECEMBER 31 2023				
REPORTING CURRENCY:		NAIRA				
Opening cash Balances		Reference to Detail	Current	Year to Date	Cumulative to December 31 2023	
	IDA Designated Account		124,684.79	26,854,392.64	30,830,576.23	
	Project Bank Accounts -Sustainability Account (ACEGID IGR)		196,268,964.31	347,856,763.91	643,666,474.66	
	Others - ESCROW			-	93,165,315.51	
Cash-in hand		-	-			
TOTAL OPENING BALANCES A			196,393,649.10	374,711,156.54	767,662,366.40	
Add: Funds Received during the quarter/Period						
IDA Designated Account				103,060,202.69	1,250,058,698.92	
Project Bank Accounts -School & Training Fees and Others (ACEGID IGR)			146,571,527.17	231,642,308.41	401,145,453.96	
Others - Interest Earned - USD Acc			351,824.47	546,988.05	573,902.01	
Loan from other projects				-	20,000,000.00	
Exchange Gain			90,398,978.60	90,398,978.60	99,687,552.33	
Refunds			11,662,099.68	31,995,832.79	449,886,471.44	
Transfer (USD to Naira A/C)			0.00	-	-	
TOTAL FUNDS RECEIVED DURING THE PERIOD B		B	248,984,429.92	457,644,310.54	2,221,352,078.66	
TOTAL FUNDS AVAILABLE C		C=(A+B)	445,378,079.02	832,355,467.09	2,989,014,445.06	
Less: Uses of funds, by Project Components		DA - ACCOUNT				
Component						
Component 1 -	1					
Goods	1		73,495,553.71	86,450,819.42	302,039,596.59	
Consultancies	1		78,976,641.96	178,332,383.36	210,881,584.96	
Training Cost	1		12,219,721.05	24,356,880.67	54,986,273.18	
Operating Cost	1		34,988,918.11	77,739,566.59	174,900,621.78	
Sub Total For Component 1			199,680,834.83	366,879,650.04	742,808,076.51	
Component 2 -	2					
Goods	2					
Works	2					
Grants & Scholarships	2					
Consultancy & Non Consultancy Services	2					
Sub Total For Component 2			-	-	-	
Sustainability Account Expenses			13,441,500.00	13,441,500.00	282,298,825.54	
Refund			12,522,942.89	35,907,866.64	1,151,005,455.65	
Transfer (USD to Naira A/C)				-	-	
Total Project Expenditure for the Period			D	225,645,277.72	416,229,016.68	2,176,112,357.69
Net Cash Available E			E=C-D	219,732,801.30	416,126,450.41	812,902,087.37
Closing bank balances						
IDA Designated Account A -USD				-		
Project Bank Accounts -School & Training Fees and Others (Sustainability Account)			219,703,934.34	415,972,898.65	760,266,289.08	
IDA Designated Account A -NAIRA			28,866.96	153,551.75	52,635,798.28	
Total Closing Bank Balances g		g	219,732,801.30	416,126,450.40	812,902,087.36	
Difference - to be explained h=f-g		h=f-g	(0.00)	(0.00)	(0.00)	

PROJECT IMPLEMENTING ENTITY:		NIGERIA			
PROJECT NAME:		African Centre of Excellence for Genomics of Infectious Diseases (ACEGID)			
IBRD CREDIT/GRANT NO.		IDA / R2014 – 0089			
REPORT:		INTERIM FINANCIAL REPORT (IFR)			
THIS SCHEDULE:		STATEMENT OF SOURCES AND USES OF FUNDS - CATEGORY			
PERIOD OF REPORT:		ENDING - DECEMBER 31 2023			
REPORTING CURRENCY:		NAIRA			
		Referece to Detail	Current Quarter	Year to Date	Cumulative to Date
Opening cash Balances					
IDA Designated Account			124,684.79	26,854,392.64	30,830,576.23
Project Bank Accounts -Sustainability Account (ACEGID IGR)			196,268,964.31	347,856,763.91	643,666,474.66
Others - ESCROW			-	-	93,165,315.51
Cash-in hand			-	-	
TOTAL OPENING BALANCES A			196,393,649.10	374,711,156.54	767,662,366.40
Add: Funds Received during the quarter/Period					
IDA Designated Account			-	103,060,202.69	1,250,058,698.92
Project Bank Accounts -School & Training Fees and Others (ACEGID IGR)			146,571,527.17	231,642,308.41	401,145,453.96
Others - Interest Earned - USD Acc			351,824.47	546,988.05	573,902.01
Loan from other projects			-	-	20,000,000.00
Exchange Gain			90,398,978.60	90,398,978.60	99,687,552.33
Refunds			11,662,099.68	31,995,832.79	449,886,471.44
TOTAL FUNDS RECEIVED DURING THE PERIOD B		B	248,984,429.92	457,644,310.54	2,221,352,078.66
TOTAL FUNDS AVAILABLE C=(A+B)		C=(A+B)	445,378,079.02	832,355,467.09	2,989,014,445.06
Less: Uses of funds, by Project Category		Category			
Eligible Expenditures Program(EEP) under Parts 1 and 2 of the Project.		1			
Goods, Works, Consultants’ services, Non Consultancy Service, Operating Costs, and Training and Workshops under Part 3 and 4 of the Project		2	225,645,277.72	416,229,016.68	2,176,112,357.69
Total Project Expenditure for the Period - By Categories		D	225,645,277.72	416,229,016.68	2,176,112,357.69
Net Cash Available E=C-D		E=C-D	219,732,801.30	416,126,450.41	812,902,087.37
Closing bank balances					
IDA Designated Account A -USD			-	-	-
Project Bank Accounts -School & Training Fees and Others (Sustainability Account)			219,703,934.34	415,972,898.65	415,972,898.65
Project Bank Accounts			28,866.96	153,551.75	153,551.75
Total Closing Bank Balances g		g	219,732,801.30	416,126,450.40	416,126,450.40
Difference - to be explained h=f-g		h=f-g	0.00	0.00	



PROJECT IMPLEMENTING ENTITY:	NIGERIA		
PROJECT NAME:	African Centre of Excellence for Genomics of Infectious Diseases (ACEGID)		
IBRD CREDIT/GRANT NO.	IDA / R2014 – 0089		
REPORT:	INTERIM FINANCIAL REPORT (IFR)		
THIS SCHEDULE:	Designated Account Reconciliation Statement		
PERIOD OF REPORT:	ENDING - DECEMBER 31 2023		
REPORTING CURRENCY:	NAIRA		
PART I		In [Naira]	In [Naira]
1. Cumulative advances to the end of current reporting period			1,250,058,698.92
2. Cumulative expenditures to the end of last reporting period		2,176,112,357.69	
3. Outstanding advance to be accounted for (Line 1 minus Line 2)			(926,053,658.77)
PART II			
4. Opening DA balance at beginning of reporting period, as of			(926,053,658.77)
5. Add/subtract: cumulative adjustments, if any		-	
6. Add: Advances from World Bank during current reporting period		-	
7. Add Line 5 and Line 6			-
8. Outstanding advances to be accounted for (Add Line 4 and Line 7)			(926,053,658.77)
9. Closing DA balance at end of current reporting period, as of			-
10. Add/subtract: cumulative adjustments, if any			
11. Add/subtract: Expenditures for the current reporting period		225,645,277.72	
12. Add Line 10 and Line 11			225,645,277.72
13. Add Line 9 and Line 12			225,645,277.72
14. Difference, if any (Line 8 minus Line 13)			(1,151,698,936.49)
PART III			
15A. Total forecast amount to be paid by World Bank			-
15B. WA#xxx sent but not yet received			
15C. Total adjusted forecast amount to be paid by World Bank (Line 15A minus Line 15B)			-
16. Less: Closing DA balance after adjustments		(1,151,698,936.49)	
17. Adjustments (if any)		-	
18. Add Line 16 and Line 17			(1,151,698,936.49)
19. Cash requirement from World bank for next two reporting periods (Line 15C minus Line 18)			1,151,698,936.49

**Name of Implementing Agency:** African Centre of Excellence for Genomics of Infectious Diseases (ACEGID)

Institutional Code : IDA / R2014 – 0089

IDA / R2014 - 0089

Reporting Period	December 31, 2023
------------------	-------------------

December 31, 2023

Eligible Expenditure Program Statement															
		Actual Expenditures (NGN)													
Budget line	Code	Annual Budget	January	February	March	April	May	June	July	August	September	October	November	December	Total Expenditures
	700000	Personal Cost	1,502,140,567.84	80,055,983.38	81,463,674.63	86,177,198.20	92,070,440.17	88,933,696.24	88,722,017.30	134,143,602	137,693,114	134,630,731	131,078,676	137,217,406	1,389,986,793.78
		Personal													
Budget line	Code	Total Overhead Cost													
	6179473	Stipendships	611,263,416.17												611,263,416.17
		Overhead Costs	1,603,916,667.00	98,614,910.71	67,929,030.96	76,657,829.27	104,982,883.92	111,878,195.88	92,410,027.8	102,787,145	161,409,924	60,665,630	1,424,961,988.02	68,665,630	1,424,961,988.02
	Total		3,722,321,041.01	179,256,679.49	180,112,985.34	153,106,226.15	168,258,760.44	193,793,529.36	418,414,182.55	216,552,630.30	633,840,705.06	234,424,986.42	298,636,928.48	216,647,438.33	3,465,206,178.40